Gene · 54915
Papers3,036
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,036
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mechanistic Insights and Clinical Implications of ELK1 in Solid Tumors: A Narrative Review. | Cells | 2025 | 40862737 | PubTator, text mining | PubMed |
| The expression of transmembrane channel-like 5 in gastric cancer and its impact on tumor progression. | Sci Rep | 2025 | 40851023 | PubTator, text mining | PubMed |
| METTL14/YTHDF1 mediates m6A modification of PTBP1 to regulate PDGF-BB-induced airway smooth muscle cell function. | Exp Lung Res | 2025 | 40847637 | PubTator, text mining | PubMed |
| Clinical and prognostic significance of m6A hypomethylation and IGF2BP3 overexpression in gastric cancer: an integrated epigenomic-transcriptomic analysis. | Hum Genomics | 2025 | 40847370 | PubTator, text mining | PubMed |
| mRNA decapping enzyme2 DCP2 expression correlates with progression and prognosis of hepatocellular carcinoma. | Sci Rep | 2025 | 40841564 | PubTator, text mining | PubMed |
| METTL3 and METTL14 drive pancreatic adenocarcinoma progression via m6A-dependent alternative splicing in PANC-1 cells. | Discov Oncol | 2025 | 40836174 | PubTator, text mining | PubMed |
| Emerging implications of N6-methyladenosine in prostate cancer progression and treatment. | Cell Death Discov | 2025 | 40830264 | PubTator, text mining | PubMed |
| Comprehensive bioinformatics analysis of EXOSC family genes in head and neck squamous cell carcinoma. | Sci Rep | 2025 | 40830179 | PubTator, text mining | PubMed |
| Identification of a Selective YTHDF1 Inhibitor Targeting the m6A Recognition Domain for Breast Cancer. | Angew Chem Int Ed Engl | 2025 | 40827557 | PubTator, text mining | PubMed |
| Investigating the Oncogenic and Immunological Implications of YTHDF1 in Ovarian Cancer. | Biologics | 2025 | 40822676 | PubTator, text mining | PubMed |
| The role of m5C, m1A and m7G modifications in tumors of urinary system. | Front Cell Dev Biol | 2025 | 40809690 | PubTator, text mining | PubMed |
| Exosome-delivered METTL14 drives hypoxia-induced proliferation, metastasis, and glycolysis of breast cancer cells through regulating TRIM16-mediated FGF7 ubiquitination. | Breast Cancer Res | 2025 | 40796898 | PubTator, text mining | PubMed |
| Epigenetic modulation with nanosatellite triggers tumoricidal immunity for hepatocellular carcinoma treatment. | Nat Commun | 2025 | 40781069 | PubTator, text mining | PubMed |
| ZC3H13 mediates N6-methyladenosine modification of SNTB1 to promote epithelial-mesenchymal transition in gastric cancer. | Cell Death Dis | 2025 | 40774945 | PubTator, text mining | PubMed |
| RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications. | MedComm (2020) | 2025 | 40761481 | PubTator, text mining | PubMed |
| Methylation of PRDX3 Expression Alleviate Ferroptosis and Oxidative Stress in Patients with Osteoarthritis Cartilage Injury. | Arch Rheumatol | 2025 | 40757971 | PubTator, text mining | PubMed |
| Exosomes in ovarian cancer: Impact on drug resistance and advances in SERS detection techniques. | J Pharm Anal | 2025 | 40757000 | PubTator, text mining | PubMed |
| KIAA1429-mediated ZFPM2-AS1 m6A modification promotes the proliferation, migration and invasion of osteosarcoma cells. | Oncol Lett | 2025 | 40747381 | PubTator, text mining | PubMed |
| The role of epigenetics in pulmonary fibrosis: recent advances in mechanistic insights and therapeutic implications. | Front Mol Biosci | 2025 | 40746422 | PubTator, text mining | PubMed |
| Correction: N6-Methyladenosine Reader YTHDF1 Promotes Stemness and Therapeutic Resistance in Hepatocellular Carcinoma by Enhancing NOTCH1 Expression. | Cancer Res | 2025 | 40746071 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/54915/papers?page=9